Advances in cord blood transplants in adults

Phuong L Doan¹ and Nelson J Chao^{1,2*}

Addresses: ¹1146 N Pavilion Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA; ²1146 N Pavilion Department of Immunology, Duke University, Durham, NC 27710, USA

* Corresponding author: Nelson J Chao (nelson.chao@duke.edu)

FI000 Medicine Reports 2010, **2**:12 (doi:10.3410/M2-12)

The electronic version of this article is the complete one and can be found at: <http://fi000.com/reports/medicine/content/2/12>

Abstract

Umbilical cord blood is an acceptable source of hematopoietic stem cells for patients with malignant diseases but has limitations in its use. In this review, we will discuss these limitations and the recent advances in cord blood transplants that may enable cord blood to become more widely available as an alternative stem cell source for adults for the treatment of malignant diseases and for use in regenerative medicine.

Introduction and context

High-dose chemotherapy with hematopoietic stem cell (HSC) rescue is a potential cure for patients with hematologic diseases, but only one-third of patients will have suitable matched related donors. Because of this limitation, alternative stem cell sources such as cord blood have been studied [1,2]. Umbilical cord blood was introduced as an alternative source of allogeneic HSCs after the success of cord transplantation in a child with Fanconi's anemia [3]. Since then, over 8000 cord blood transplantations have been performed internationally. We will highlight key studies of cord blood transplants in adults.

The selection for the best cord blood unit is based on human leukocyte antigen (HLA) matching 6/6 and a nucleated cell dose of more than 3×10^6 cells per kilogram [4]. Because this cell dose is difficult to achieve in adults by using a single cord unit, two cord blood units rather than one partially HLA-matched unit has been studied and shown to have a median engraftment of 23 days and have disease-free survival at 1 year in 57% of patients but carries an increased risk of acute graft-versus-host disease (GVHD) [5]. The increased risk of GVHD is associated with three risk factors: (a) the use of two units compared with one unit, (b) a nonmyeloablative preparative regimen compared with myeloablative regimens, and (c) the lack of antithymocyte globulin

in the preparative regimen [6]. Because of the risk of acute GVHD, dual-cord transplants result in higher early transplant-related mortality compared with single-cord transplants but have less transplant-related mortality at 1 year and may have greater graft-versus-leukemia effect [7,8]. To clarify these issues, randomized studies of dual-cord versus single-cord transplants in pediatric populations are under way. To date, however, the role of dual-cord versus single-cord transplants in adults remains unclear.

Because myeloablative conditioning regimens in cord blood transplants result in high transplant-related mortality, nonmyeloablative regimens have been studied to determine whether reliable engraftment can be achieved with less toxicity [9-11]. These nonmyeloablative regimens in cord blood transplants have yielded similar results for safety, engraftment, and survival when compared with matched sibling donors [12,13]. In a recent review, Cutler and Ballen [14] discussed these issues in more detail. Based on these studies, nonmyeloablative conditioning regimens have been shown to be a feasible alternative for patients who otherwise would not have been able to tolerate myeloablative regimens.

Recent advances

In this section, we will discuss the use of cord blood transplantations in regenerative medicine and evaluate

novel methods for *ex vivo* expansion of HSCs. The purpose of using stem cells in regenerative medicine is to restore normal or improved physiology to damaged organs. Embryonic stem cells, fetal tissue stem cells, adult tissue stem cells, and umbilical cord blood stem cells have been evaluated for these studies [15]. Of these stem cells, cord blood stem cells carry several advantages since they are readily available and pose no risk to donors for collection. In preclinical studies, cord blood stem cells have been shown to form long-lasting blood vessels *in vivo* (thus holding potential in wound-healing models), form cardiomyocytes in acute myocardial ischemia models, and reduce neurologic deficits in stroke injury models [16-18]. While these studies hold promise, they have not been translated into prospective clinical studies due to the high toxicity of immune suppression and high transplant-related mortality.

To overcome the limitation of low cell dose and delayed engraftment in cord blood transplants, *ex vivo* expansion of HSCs in cord blood has been extensively studied and recently reviewed [19,20]. Initial studies were disappointing with the expansion of committed rather than primitive HSCs. Co-culture of HSCs with early-acting cytokines such as stem cell factor, FMS-related tyrosine kinase, and thrombopoietin yields the greatest expansion, with the most prolific expansion reported to be 146,000-fold [21]. One of the first clinical studies to evaluate the safety and feasibility of using *ex vivo* expansion of cord blood cells with cytokines in patients with hematologic malignancies and breast cancer demonstrated a 100% neutrophil engraftment but resulted in an increased risk of acute grade III-IV GVHD compared with patients who had received unmanipulated blood [22,23]. At this time, additional clinical studies are required before cellular expansion can be done routinely.

Implications for clinical practice

The innovative use of dual-cord blood units and the feasibility of nonmyeloablative regimens to treat patients allow more patients to undergo transplantation with the hope of achieving a cure. It has already been shown that cord blood transplants have similar disease-free survival and transplant-related mortality when compared with matched unrelated bone marrow transplants in children and adults [24,25]. For now, it is still to be determined whether cord blood should be preferred over matched unrelated donor or partially matched donor cells. Also, specific diseases and disease stages for which cord blood is preferred over these other cell sources are still unknown. With the growing number of adult patients receiving cord blood transplants, we hope to be able over the next few years to clarify when cord blood is the best donor cell choice for allogeneic transplantation.

Abbreviations

GVHD, graft-versus-host disease; HLA, human leukocyte antigen; HSC, hematopoietic stem cell.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by grant 5RO1-HL62095 to NJC from the National Institutes of Health.

References

1. Gluckman E, Rocha V, Boyer-Chamhard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte JP, Fernandez M, Chastang G: **Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group.** *N Engl J Med* 1997, **337**:373-81.
2. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J: **Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.** *N Engl J Med* 2001, **344**:1815-22.
3. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P, Cooper S, English D, Kurtzberg J, Bard J, Boyse E: **Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling.** *N Engl J Med* 1989, **321**:1174-8.
4. Gluckman E, Rocha V: **Donor selection for unrelated cord blood transplants.** *Curr Opin Immunol* 2006, **18**:565-70.
5. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, Verfaillie CM, Wagner JE: **Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.** *Blood* 2005, **105**:1343-7.
6. Macmillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR, Blazar BR, Wagner JE: **Acute graft-versus-host disease after unrelated donor umbilical cord transplantation: analysis of risk factors.** *Blood* 2008, **113**:2410-5.
7. Verneris MR, Brunstein CG, Barker J, Macmillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE: **Relapse risk after umbilical cord blood transplantation: enhanced graft versus leukemia effect in recipients of two units.** *Blood* 2009, **114**:4293-9.
8. Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ: **Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.** *J Clin Oncol* 2009, **27**:3634-41.
9. Rizzieri DA, Long GD, Vredenburg JJ, Gasparetto C, Morris A, Stenzel TT, Davis P, Chao NJ: **Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.** *Blood* 2001, **98**:3486-8.
10. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE: **Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord transplantation after reduced-intensity conditioning.** *Blood* 2003, **102**:1915-9.
11. Koh L-P, Chao NJ: **Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens.** *Biol Blood Marrow Transplant* 2004, **10**:1-22.
12. Majhail NS, Weisdorf DJ, Wagner JE, DeFor TE, Brunstein CG, Burns LJ: **Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell**

transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. *Blood* 2006, **107**:3804-7.

13. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, McGlave PB, Wagner JE: **Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.** *Blood* 2007, **110**:3064-70.

Changes Clinical Practice

F1000 Factor 4.8 *Must Read*

Evaluated by Ignazio Majolino 25 Nov 2007, Karen Ballen 21 Apr 2008

14. Cutler C, Ballen K: **Reduced-intensity conditioning and umbilical cord blood transplantation in adults.** *Bone Marrow Transplant* 2009, **44**:667-71.
15. Mimeault M, Hauke R, Batra SK: **Stem cells: a revolution in therapeutics- recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies.** *Clin Pharmacol Ther* 2007, **82**:252-64.
16. Au P, Dahern LM, Duda DG, Cohen KS, Tyrrell JA, Lanning RM, Fukumura D, Scadden DT, Jain RK: **Differential *in vivo* potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels.** *Blood* 2008, **111**:1302-5.
17. Nishiyama N, Miyoshi S, Hida N, Uyama T, Okamoto K, Ikegami Y, Miyado K, Segawa K, Terai M, Sakamoto M, Ogawa S, Umezawa A: **The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells *in vitro*.** *Stem Cells* 2007, **25**:2017-24.
18. Bliss T, Guzman R, Daadi M, Steinberg GK: **Cell transplantation therapy for stroke.** *Stroke* 2007, **38**:817-26.
19. Kelly SS, Sola CB, de Lima M, Shpall E: **Ex vivo expansion of cord blood.** *Bone Marrow Transplant* 2009, **44**:673-81.

20. Broxmeyer HE, Cooper S, Hass DM, Hathaway JK, Stehman FB, Hangoc G: **Experimental basis of cord blood transplantation.** *Bone Marrow Transplant* 2009, **44**:627-33.

21. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Fagioli F, Berger M, Aglietta M: **Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood.** *Blood* 1997, **89**:2644-53.
22. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK: **Transplantation of ex vivo expanded cord blood.** *Biol Blood Marrow Transplant* 2002, **8**:368-76.
23. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NK, McGlave PB, Sender L, Cairo MS: **Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease.** *Blood* 1996, **88**:795-802.
24. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, Loberiza FR, Champlin RE, Klein JP, Horowitz MM, Wagner JE: **Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study.** *Lancet* 2007, **369**:1947-54.

Changes Clinical Practice

F1000 Factor 6.5 *Must Read*

Evaluated by Paola Rebulla 28 Jun 2007, Arnon Nagler 31 Oct 2007, Ignazio Majolino 23 Nov 2007

25. Takahasi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, Fukono K, Uchiyama M, Takasugi K, Iseki T, Tojo A, Yamaguchi T, Asano S: **Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen.** *Blood* 2007, **109**:1322-30.